Wedbush analyst Robert Driscoll initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target Discover the ...

U.S. stocks fell Thursday afternoon, with the S&P 500 (SP500) pulling back from a record high, in part as investors balked at ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

U.S. defense stocks opened in the red on Thursday, Feb. 20 following reports that President Donald Trump’s administration has ...

Palantir Technologies received a new Buy rating from Loop Capital and continued bullish support from Wedbush on Thursday, despite recent market concerns over potential U.S. defense budget cuts.

Wedbush reiterated its outperform rating on TSLA with a $550 price target, representing a 55.08% increase from the current ...

Investing.com -- Palantir Technologies Inc (NASDAQ: PLTR) stock plummeted sharply again Thursday following news that CEO Alex ...

Palantir (PLTR) stock is tumbling 11% after its CEO implemented a new stock-trading plan and a report stated that the ...

Palantir has seen its stock skyrocket over the past year, owing partly to momentum for the company's Artificial Intelligence Platform, or software better known as AIP. Overall revenue grew sizably ...

If the Department of Defense goes through budget cuts as suggested by a leaked memo, Palantir Technologies (PLTR) would have ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their ...

Principal Securities Inc. raised its position in shares of VICI Properties Inc. (NYSE:VICI – Free Report) by 32.6% in the ...